Monika Schmelz

  • 1703 Citations
  • 19 h-Index
1986 …2018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Monika Schmelz is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles
Desmogleins Medicine & Life Sciences
Desmosomes Medicine & Life Sciences
Cadherins Medicine & Life Sciences
Desmoplakins Medicine & Life Sciences
Histocompatibility Antigens Class II Medicine & Life Sciences
B-Cell Lymphoma Medicine & Life Sciences
Glycoproteins Medicine & Life Sciences
Epithelial Cells Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1986 2018

  • 1703 Citations
  • 19 h-Index
  • 34 Article
  • 1 Conference contribution
2 Citations (Scopus)

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

Kelly, K. R., Friedberg, J. W., Park, S. I., McDonagh, K., Hayslip, J., Persky, D., Ruan, J., Puvvada, S. D., Rosen, P., Iyer, S. P., Stefanovic, A., Bernstein, S. H., Weitman, S., Karnad, A., Monohan, G., VanderWalde, A., Mena, R., Schmelz, M., Perry, C. S., Groshen, S. & 5 others, Venkatakrishnan, K., Zhou, X., Sheldon-Waniga, E., Jane Leonard, E. & Mahadevan, D., Dec 15 2018, In : Clinical Cancer Research. 24, 24, p. 6150-6159 10 p.

Research output: Contribution to journalArticle

Aurora Kinase A
Vincristine
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Lymphoma, Large B-Cell, Diffuse
4 Citations (Scopus)

Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma

Kendrick, S., Rimsza, L. M., Scott, D. W., Slack, G. W., Farinha, P., Tan, K. L., Persky, D., Puvvada, S. D., Connors, J. M., Sehn, L., Gascoyne, R. D. & Schmelz, M., Jan 1 2017, In : Virchows Archiv. 470, 1, p. 113-117 5 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma

Puvvada, S. D., Guillén-Rodríguez, J. M., Rivera, X. I., Heard, K., Inclan, L., Schmelz, M., Schatz, J. H. & Persky, D. O., Sep 5 2017, (Accepted/In press) In : Oncology (Switzerland).

Research output: Contribution to journalArticle

Lymphoma
Lymphoma, Large B-Cell, Diffuse
Major Histocompatibility Complex
Biomarkers
Histone Deacetylases

Come in Out of the Cold: Alternatives to Freezing for Microbial Biorepositories

Isaacs, E. & Schmelz, M., Feb 15 2017, In : Clinical Microbiology Newsletter. 39, 4, p. 27-34 8 p.

Research output: Contribution to journalArticle

Nucleic Acids
Freezing
Technology
Costs and Cost Analysis
Quality Control
15 Citations (Scopus)

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520

Puvvada, S. D., Li, H., Rimsza, L. M., Bernstein, S. H., Fisher, R. I., LeBlanc, M., Schmelz, M., Glinsmann-Gibson, B., Miller, T. P., Maddox, A. M., Friedberg, J. W., Smith, S. M. & Persky, D. O., Jan 12 2016, (Accepted/In press) In : Leukemia and Lymphoma. p. 1-11 11 p.

Research output: Contribution to journalArticle

Histocompatibility Antigens Class II
B-Cell Lymphoma
Tumor-Infiltrating Lymphocytes
T-Lymphocytes
Tumor Microenvironment